Skip to main content

Agilent Technologies, MRM Strike Co-marketing Pact

NEW YORK (GenomeWeb News) – Agilent Technologies said today that it has entered into a co-marketing agreement with MRM Proteomics that will enable the firms to offer more complete hardware, software, and proteomics kit solutions.

Vancouver-based MRM provides protein quantitation, biomarker, and proteomic services to pharmaceutical, biotech, and diagnostics customers. The company specializes in providing highly multiplexed quantitation of proteins in biosamples from blood, cerebrospinal fluid, and urine, using isotopically labeled internal standards.

"The agreement is a further reflection of Agilent's continued commitment and investment in quantitative proteomics," Agilent Metabolomics and Proteomics Marketing Manager Steve Fischer said in a statement.

The Scan

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.